SHANGHAI and SUZHOU, China, Feb. 26, 2019 /PRNewswire/ Gracell Biotechnologies, Co., Ltd. (“Gracell”) announced the completion of its $85 million series B funding today. The financing was led by Temasek with Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji also participated in the round. This new funding will enable Gracell to enter clinical trials with several of its next generation immune cell gene therapy candidates.